In the unadjusted model (Model 1), compared with empagliflozin, the risks of dapagliflozin, canagliflozin, and other SGLT2 inhibitors for HF, MI, AP, stroke, and AF were not statistically different. This evidence concerns the gene SLC5A2 and stroke disorder.